Category: Clinical Trials
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Clinical Trial Spotlight: Tumor-Infiltrating Lymphocyte Therapy for ALK-Positive NSCLC at Moffitt Cancer Center
For ALK-positive patients who have progressed after targeted therapy, a new clinical trial at Moffitt Cancer Center offers renewed hope. This Phase 1 study explores an enhanced form of Tumor-Infiltrating Lymphocyte (TIL) therapy—empowering a patient’s own immune cells with a genetic boost to better recognize and fight cancer. With its focus on ALK, EGFR, ROS1,…
-
Patient Spotlight: Rick Meyer
We interviewed long term survivor Rick Meyer on his experience with multiple ALK TKIs, his participation in the Nuvalent clinical trial for almost two years and counting, and his overall attitude to life as a thriving ALK patient.
-
Clinical Trials for ALK-positive Cancers – Are They for Me?
Should I enroll in a clinical trial for ALK-positive cancer? The decision to enroll in a clinical trial requires a real understanding of what is being studied and how you will participate in the study. It is important to remember that clinical trials have been instrumental in developing all treatments for ALK-positive cancers. Many of…
-
Amivantamab With Tyrosine Kinase Inhibitors (TKIs) for Advanced NSCLC With ALK, ROS1, or RET Alterations
Who is this trial for: This trial is for patients with one of three forms of non-small cell lung cancer (NSCLC) – ALK, ROS1, or RET – who are progressing on their current TKI under certain conditions, and are willing to try an experimental drug combination in order to extend the life of their current…
-
Phase II Clinical Trial NCT05384626 by Nuvalent, Inc. A Study of NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Who is this trial for: NVL-655 is a 4th generation, brain-penetrant, ALK TKI inhibitor created to overcome several limitations observed with currently available therapies. NVL-655 is designed to have activity in tumors that have developed resistance to first, second, and third-generation ALK inhibitors, including tumors with the solvent front G1202R mutation or compound mutations G1202R/L1196M…
-
ALKOVE-1 Study Results Summary: NVL-655’s Promising Role in Treating Advanced ALK+ Lung Cancer
The clinical results from the Phase 1 portion of the ALKOVE-1 study is bringing new hope to patients with ALK-positive lung cancer, especially those who have exhausted other treatment options. NVL-655, a fourth-generation ALK inhibitor, has shown unique effectiveness in overcoming resistance to previous treatments, including those with brain metastases and specific resistance mutations
-
ALK Clinical Trials September 2024: Should Brain Metastases be Treated with Radiation at Diagnosis in ALK+ Lung Cancer? Research About a Crucial Question
For those facing the challenging diagnosis of ALK-positive lung cancer, brain metastases often pose a serious concern. Research reveals that up to 40% of these patients have brain metastases right from the start. This sets the stage for a critical question in treatment planning: Is it better to tackle these brain metastases with spot radiation,…
-
MEET THE PATIENTS WHERE THEY ARE: a new perspective on translational research in the field to accelerate precision oncology
Team members of the Judith Tam ALK Lung Cancer Research Initiative ventured out to Nashville on July 18th for the 2024 ALK Positive Summit, to embark on an unprecedented research blood collection which took place July 19th and 20th. This was the culmination of 5 months of intense visioning with ALK Positive, Inc and sculpting…
-
Discovering Insights Beyond Clinical Trials: Exploring ALK-Positive Lung Cancer Treatment
Clinical trials are the gold standard for evaluating new treatments in medicine. They offer a structured approach, where patient groups are carefully selected, treatments are administered, and results are meticulously followed over time. This controlled environment allows for a deep understanding of how treatments perform in specific patient populations, free from the confounding factors that…
-
Gilteritinib for the Treatment of ALK positive non-small cell lung cancer (NSCLC)
This trial is for patients with Stage 4 ALK positive NSCLC that have progressed on an earlier generation ALK TKI AND lorlatinib, and on any number of other standard-of-care or trial treatments. The trial drug is gilteritinib (aka Xospata), which was approved by the FDA in 2018 for a type of leukemia, but has been…
-
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
CAMBRIDGE, Mass., May 16, 2024 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to NVL-655 for the treatment of patients with locally advanced or…
-
The Global Landscape of Research: ALK-Positive Cancer Therapeutic Trials Worldwide
In the ever-evolving arena of ALK-positive cancer therapies, clinical trials offer patients not only cutting-edge interventions but also a chance to contribute to the advancement of ALK cancer treatment. In examining international ALK cancer trials, we uncover both challenges and opportunities for those seeking innovative treatments beyond conventional options. ALK Positive is the first foundation…